ArticleAnnals of laboratory medicine2026
Identification of Metabolic Biomarkers in Bone Marrow Aspirate for Diagnosis, Prognosis, and Therapeutic Monitoring in Pediatric Langerhans Cell Histiocytosis.
Article in Annals of laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic reprogramming is frequently observed but poorly understood in Langerhans cell histiocytosis (LCH), a rare inflammatory myeloid neoplasm. To improve molecular classification, treatment monitoring, and prognosis, we comparatively analyzed metabolite alterations in bone marrow aspirates (BMAs) from patients with various subtypes of LCH and healthy individuals. Methods: Metabolite alterations in BMAs were identified using untargeted metabolomic profiling and quantified using targeted metabolomics. ROC curve and Kyoto Encyclopedia of Genes and Genomes analyses were used to identify potential metabolic biomarkers for diagnosis, prognosis, and therapeutic monitoring in pediatric LCH. Results: The major metabolites altered in LCH included lipid/lipid-like molecules and organic acids and their derivatives, primarily involved in pathways related to choline metabolism, glycerophospholipid metabolism, and unsaturated fatty acid biosynthesis. Nine metabolites were identified as potential diagnostic biomarkers. 1-Heptadecanoyl-sn-glycero-3-phosphocholine (PC[17:0/0:0]) levels varied significantly among LCH clinical subtypes. L-kynurenine and betaine aldehyde levels helped in effectively distinguishing inflammatory from cancer-like LCH, and increased L-kynurenine and 2-arachidonoyl-1-stearoyl-snglycero-3-phosphoethanolamine levels and reduced PC(17:0/0:0) levels predicted poor prognosis. Several metabolites, including dodecanoic acid and inosine, may serve as indicators for treatment efficacy assessment in LCH with multisystem and risk organ involvement. L-kynurenine and betaine aldehyde levels were verified using targeted quantitative metabolomics, and their clinical significance was assessed. Conclusions: Alterations in BMA metabolic profiles within the LCH population and in specific metabolites may provide valuable insights into LCH pathogenesis and serve as biomarkers for diagnosis, prognosis, and therapeutic response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.